From Drug Target Inhibition to Degradation: a TACtical Strategy - Nature Biopharma Dealmakers Back Bay in the NewsBack Bay Life Science AdvisorsJune 2, 2022IPOs, VC, Drug Development, Investment Banking
Back Bay in Wall Street Journal, Pro Venture Capital: Medical-Device IPOs, Acquisitions Jumped in 2021 Media CoverageBack Bay Life Science AdvisorsJanuary 15, 2022Investing, Medical Device, IPOs, M&A
Creating the Optimal Term Sheet Investment Banking TeamApril 21, 2021Investment Banking, Term Sheets, IPOs
2020 IPO Class Performance Investment Banking Update, BlogBack Bay Life Science AdvisorsSeptember 23, 2020Biotech Financing, IPOs, Biotech, Investment Banking
